Format

Send to

Choose Destination
J Nucl Med. 2017 Dec;58(12):1956-1961. doi: 10.2967/jnumed.117.192476. Epub 2017 May 18.

Impact of 68Ga-PSMA-11 PET on Management in Patients with Biochemically Recurrent Prostate Cancer.

Author information

1
Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California thomas.hope@ucsf.edu.
2
Department of Radiology, San Francisco VA Medical Center, San Francisco, California.
3
UCSF Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California.
4
Division of Hematology/Oncology, Department of Medicine, University of California San Francisco, San Francisco, California.
5
Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California.
6
Department of Urology, University of California San Francisco, San Francisco, California; and.
7
Department of Radiation Oncology, University of California San Francisco, San Francisco, California.

Abstract

The purpose of this prospective study was to estimate the effect of 68Ga-labeled prostate-specific membrane antigen (PSMA)-11 PET on the intended management of patients with biochemically recurrent prostate cancer. Methods: Pre- and postimaging surveys were filled out by the referring providers for patients with biochemical recurrence who were imaged using 68Ga-PSMA-11 PET. The inclusion criterion for this study was a prostate-specific antigen (PSA) doubling time of less than 12 mo after initial treatment (NCT02611882). Of the 150 consecutive patients imaged, 126 surveys were completed (84% response rate). The responses were categorized as major change, minor change, no change, or unknown change. Results: There were 103 patients (82%) with disease detected on 68Ga-PSMA-11 PET. On the basis of the survey results, there were 67 patients (53.2%) with major changes in management and 8 patients (6.4%) with minor changes. The proportion of cases resulting in a change in management did not significantly differ by baseline PSA level. In patients with PSA levels below 0.2 ng/dL, 7 of 12 patients had disease detected on 68Ga-PSMA-11 PET, 5 of whom had a major change in management. Conclusion:68Ga-PSMA-11 PET resulted in a major change in management in 53% of patients with biochemical recurrence. Further studies are warranted to investigate whether PSMA-based management strategies result in improved outcomes for patients.

KEYWORDS:

PET; biochemical recurrence; management; molecular imaging; prostate cancer; prostate-specific membrane antigen

PMID:
28522741
DOI:
10.2967/jnumed.117.192476
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center